APA (7th ed.) Citation

H, G., C, K., P, G., D, K., L, G., M, E., . . . JJ, K. (2020). Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study. The Lancet. Haematology, 7(3), e196. https://doi.org/10.1016/S2352-3026(19)30236-4

Chicago Style (17th ed.) Citation

H, Gisslinger, et al. "Ropeginterferon Alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study." The Lancet. Haematology 7, no. 3 (2020): e196. https://doi.org/10.1016/S2352-3026(19)30236-4.

MLA (9th ed.) Citation

H, Gisslinger, et al. "Ropeginterferon Alfa-2b Versus Standard Therapy for Polycythaemia Vera (PROUD-PV and CONTINUATION-PV): A Randomised, Non-inferiority, Phase 3 Trial and Its Extension Study." The Lancet. Haematology, vol. 7, no. 3, 2020, p. e196, https://doi.org/10.1016/S2352-3026(19)30236-4.